Skip to main content

Investors

Press Releases

Overview
Press Releases     
 Events + Presentations
Company Information
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
News Alerts

Recent Press Releases

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Cidara Therapeutics to Participate in November Investor Conferences
Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025
Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10th ESWI Influenza Conference 2025
Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention
Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic
Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
Cidara Therapeutics to Participate in September Investor Conferences
Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Cidara Announces Pricing of Upsized Public Offering of Common Stock
Cidara Announces Proposed Public Offering of Common Stock
Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza
Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development
Cidara Therapeutics to Participate in The Citizens Life Sciences Conference
Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response
Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza
Cidara Therapeutics Announces $105 Million Private Placement
Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences
Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388
Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
Cidara Therapeutics Announces Reverse Stock Split
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
Cidara Therapeutics Named as a San Diego Metro Area Top Workplace
Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38th Annual Meeting
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)
Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023
Cidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference
Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza
Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Cidara Therapeutics Provides Update on REZZAYO™ (rezafungin for injection)
Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program
Cidara Therapeutics Added to Russell Microcap® Index
Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B
Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit
Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
Cidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases Conference
Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™
Cidara Therapeutics to Participate in Upcoming Investor Conferences
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress
Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares in Public Offering of Common Stock
Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock
Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock
Cidara Therapeutics Announces Promising Interim Phase 2a Data Assessing the Safety and Efficacy of a Single Dose of CD388 in an Influenza Challenge Model
Cidara to Present at ESMO Targeted Anticancer Therapies Congress
Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara’s CD73 Oncology DFC Program
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform
Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388
Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split
Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet
Cidara Therapeutics to Participate in the World Antiviral Congress 2022
Cidara Therapeutics to Present at the Stifel Healthcare Conference
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma
Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza
Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.
Cidara Therapeutics to Host Research and Development Day
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and/or Invasive Candidiasis at ECCMID 2022
Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Cidara Therapeutics Named A San Diego Metro Area Top Workplace For The Fifth Consecutive Year
Cidara Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred Stock
Cidara Therapeutics Announces Commencement of Concurrent Public Offerings of Common Stock and Preferred Stock
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cidara Therapeutics to Present New Data for Rezafungin at TIMM Congress
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2021
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
Cidara Therapeutics to Host Research and Development Day
Cidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary
Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Cidara Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress
Cidara Therapeutics Presents New Analyses from Multiple Rezafungin Studies at ECCMID 2021
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cidara Therapeutics Provides Leadership Update
Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Cidara Therapeutics to Participate in the Raymond James Human Health Innovation Conference
Cidara to Present at Mycology 2021 Conference
Cidara Provides Corporate Update and Reports First Quarter 2021 Financial Results
Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cidara Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Cidara Therapeutics Announces New Data for Rezafungin at the 21st ICHS Symposium
Cidara Therapeutics to Present New Data for Rezafungin and Influenza AVCs at the 21st ICHS Symposium
Cidara Therapeutics Announces Key Additions to its Board of Directors
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations
Cidara Therapeutics to Present Preclinical Data for Influenza AVCs at the 7th ESWI Influenza Conference
Cidara Therapeutics to Present New Clinical Data for Rezafungin at ESICM LIVES 2020
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Fourth Consecutive Year
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
Cidara Provides Corporate Update and Reports Third Quarter 2020 Financial Results
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020
Cidara Therapeutics to Present at the 2020 American College of Clinical Pharmacy (ACCP) Annual Meeting
Cidara Therapeutics to Present New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020
Cidara Therapeutics to Participate in Upcoming Investor Conferences
Cidara Provides Corporate Update and Reports Second Quarter 2020 Financial Results
Cidara Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Cidara Therapeutics Announces Formation of Scientific Advisory Board
Cidara Therapeutics to Participate in B. Riley Virtual Summer Series Panel on Antiviral Therapeutics
Cidara Therapeutics Added to Russell 3000® Index
Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference
Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation
Cidara Provides Corporate Update and Reports First Quarter 2020 Financial Results
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference
Cidara Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
Cidara Therapeutics to Present at Transplantation & Cellular Therapy (TCT) and Mycology 2020 Medical Conferences
Cidara Therapeutics Announces Closing of Rights Offering
Cidara Therapeutics Announces Commencement of Rights Offering
Cidara Therapeutics Announces Proposed Rights Offering
Cidara Therapeutics to Present at Two Upcoming Medical Conferences
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Third Consecutive Year
Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results
Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs
Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin
Cidara Therapeutics to Present Data from its Cloudbreak Antiviral Program at the Options X for the Control of Influenza Conference
Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results
Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin
Cidara Therapeutics to Present New Data on Rezafungin and its Cloudbreak Antiviral Candidate for Influenza at ASM Microbe 2019
Cidara Provides Corporate Update and Reports First Quarter 2019 Financial Results
Cidara Therapeutics Highlights New Data from Multiple Rezafungin Studies Presented at ECCMID 2019
Cidara Therapeutics Selects First Clinical Development Candidate from its Cloudbreak Influenza (Antiviral) Program
Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
Cidara Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Cidara Therapeutics Announces Rezafungin Presentations at the 2019 European Society for Blood and Marrow Transplantation Meeting
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results
Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting
Cidara Therapeutics Appoints James Levine as CFO and Jessica Oien as General Counsel and Secretary
Cidara Therapeutics to Present New Data at ASH 2018 Highlighting Potential of Rezafungin to Prevent Invasive Fungal Infections in Bone Marrow Transplant Patients
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year
Cidara Provides Corporate Update and Reports Third Quarter 2018 Financial Results
Cidara Therapeutics to Present New Data Highlighting Its Cloudbreak Immunotherapy Platform at the 2018 World Antimicrobial Resistance Congress
Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference
Cidara Therapeutics Presents Results from Successful Phase 2 STRIVE Trial Evaluating Rezafungin at IDWeek 2018
Cidara Therapeutics Initiates Phase 3 Trial of Lead Antifungal Rezafungin for Treatment of Invasive Candida Infections
FDA Grants QIDP and Fast Track Designations to Cidara Therapeutics’ Rezafungin Prophylaxis Development Program
Cidara Therapeutics to Present at Two Upcoming Investor Conferences
Cidara Therapeutics Appoints David Gollaher, Ph.D., to Board of Directors
Cidara Therapeutics to Present Data on Lead Antifungal Rezafungin at IDWeek 2018
Cidara Therapeutics to Present New Cloudbreak Data at the ESCMID/ASM Conference and 16th Annual Discovery on Target Meeting
Cidara Provides Corporate Update and Reports Second Quarter 2018 Financial Results
Cidara Therapeutics Announces Oral Presentations on Rezafungin at Two Upcoming Global Conferences
Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara’s Rezafungin for the Treatment of Invasive Fungal Infections
Cidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH to Support Development of Novel Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial Infections
Cidara Therapeutics Announces Offering of Common Stock and Warrants
Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results
Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting
Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin
Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin
Cidara Therapeutics to Present Rezafungin Data at the European Society for Blood and Marrow Transplantation 2018 Meeting
Cidara Announces Appointment of Chrysa Mineo as Independent Director
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results
Cidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem Meeting
Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections
Cidara Therapeutics Completes Enrollment in Phase 2 STRIVE Trial Evaluating Novel Antifungal Rezafungin (CD101 IV) in Invasive Fungal Infections
Cidara Therapeutics Named a San Diego Metro Area 2017 Top Workplace
Cidara Provides Corporate Update and Reports Third Quarter 2017 Financial Results
Cidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate Update
Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock
Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology Meeting
Cidara Therapeutics to Present at Two Upcoming Conferences
Cidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance Congress
Cidara Provides Corporate Update and Reports Second Quarter 2017 Financial Results
Cidara Therapeutics Announces Publication of Results from In Vivo Study Investigating Novel Antifungal CD101 in Intra-Abdominal Candidiasis (IAC)
Cidara Therapeutics to Participate in Anti-Infectives Panel Discussion at the 2017 Infectious Diseases Summit
Cidara Therapeutics to Participate in the 2017 BIO International Convention
Cidara Therapeutics Announces Presentations at ASM Microbe 2017 and the 22nd Congress of the European Hematology Association
Cidara Provides Corporate Update and Reports First Quarter 2017 Financial Results
Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer
Cidara Therapeutics to Present Data on Novel Antifungal CD101 and Cloudbreak Antibacterial Immunotherapy at ECCMID and SID Annual Meetings
Cidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance Development of its First CloudbreakTM Antibiotic Immunotherapy
Cidara Therapeutics to Host Investor Day on April 6, 2017
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC
Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis
Newly Published Data Reinforce Growing Body of Evidence Supporting Cidara Therapeutics’ Lead Antifungal CD101
Cidara Therapeutics’ Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies
Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results
Cidara Therapeutics to Present Data on Novel Antifungal CD101 at the Global Joint Conference of ICHS and INFOCUS
Cidara Therapeutics to Present at the Stifel 2016 Healthcare Conference
Cidara Therapeutics and Square 1 Bank Announce $20 Million Credit Facility
Cidara Therapeutics Announces Data from Studies of Novel Antifungal CD101 to be Presented at ACCP and IDWeek Annual Meetings
Cidara Therapeutics Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriter’s Option to Purchase Additional Shares
Cidara Therapeutics Announces Pricing of Public Offering of Common Stock
Cidara Therapeutics Announces Commencement of Public Offering of Common Stock
Cidara Therapeutics Selects First Development Candidate from its CloudbreakTM Immunotherapy Discovery Platform
Cidara Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Cidara Therapeutics Announces Clinical Management Team Changes
Cidara Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Cidara Therapeutics Announces Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting
Cidara Therapeutics to Present at the Cantor Fitzgerald Annual Healthcare Conference
Cidara Therapeutics Expands Management Team
Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis
Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016
Cidara Therapeutics to Present at the Jefferies 2016 Healthcare Conference
FDA Grants QIDP and Fast Track Designation to CD101 Topical, Cidara Therapeutics’ Novel Antifungal Product Candidate
Cidara Reports First Quarter 2016 Financial Results and Provides Corporate Update
Cidara Therapeutics Announces Presentation of Data from its Antifungal Drug Development Programs at ECCMID 2016
Cidara Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference
Cidara Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
CORRECTING and REPLACING Cidara Receives Orphan Drug Designation for Novel Echinocandin, CD101 IV, in Candidemia and Invasive Candidiasis
Cidara Receives Orphan Drug Designation for Novel Echinocandin, CU101 IV, in Candidemia and Invasive Candidiasis
Cidara Therapeutics Announces Participation in Leerink Partners 5th Annual Global Healthcare Conference
Cidara Therapeutics Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CD101 IV
Cidara Therapeutics Commends IDSA for New Candidiasis Clinical Management Guidelines
Cidara Therapeutics Announces Positive Data From Phase 1 Clinical Trial of CD101 IV and Reports Third Quarter 2015 Financial Results
Cidara Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference in London
Cidara Therapeutics Presents Results from Key Studies Evaluating Its Novel Echinocandin CD101 at ICAAC/ICC 2015
Cidara Reports Second Quarter 2015 Financial Results and Provides Corporate Update
Cidara Therapeutics to Present Data from Antifungal Drug Development Programs at ICAAC/ICC 2015 Meeting
Cidara Therapeutics to Present at the Wedbush PacGrow 2015 Healthcare Conference
Cidara Therapeutics Initiates Phase 1 Study of Lead Antifungal Product Candidate CD101 IV
Cidara Therapeutics Set to Join Russell Indexes
Cidara Reports First Quarter 2015 Financial Results and Provides Corporate Update
FDA Grants QIDP and Fast Track Designations to CD101 IV, Cidara Therapeutics’ Lead Antifungal Product Candidate
Cidara Therapeutics Announces Pricing of Initial Public Offering
Robert Perez and Timothy Franson Join Cidara Board of Directors
Cidara Completes $42 Million Private Series B Financing
Cidara Appoints Paul Daruwala to Chief Commercial Officer and James Balkovec to SVP of Research
Cidara Named to FierceBiotech’s Fierce 15
Cidara Therapeutics to Present Data from Antifungal Drug Development Program at ICAAC
Cidara Completes $32M Series A Financing
Cidara Newsroom

Contact Us

Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive, Suite 101
San Diego, CA 92121

p: (858) 752-6170
e: info@cidara.com

ABOUT

PIPELINE

CLOUDBREAK®

PUBLICATIONS

NEWSROOM

INVESTORS

CAREERS

Subscribe

© 2025 Cidara Therapeutics, Inc. | Terms of Use | Privacy and Cookies Policy

MERCK & CO., INC., Rahway, NJ, USA

(known as MSD outside the United States and Canada)

Effective January 7, 2026, Cidara Therapeutics, Inc., is a subsidiary of Merck & Co., Inc.
(Rahway, NJ USA)

Skip to content